...
首页> 外文期刊>Journal of Hainan Medical University >Effect of Aidi injection combined with FOLFOX4 chemotherapy on tumor stem cell characteristics and antitumor immune response in patients with advanced colon cancer
【24h】

Effect of Aidi injection combined with FOLFOX4 chemotherapy on tumor stem cell characteristics and antitumor immune response in patients with advanced colon cancer

机译:艾迪注射液联合FOLFOX4化疗对晚期结肠癌患者肿瘤干细胞特性和抗肿瘤免疫反应的影响

获取原文
           

摘要

Objective: To study the effect of Aidi injection combined with FOLFOX4 chemotherapy ontumor stem cell characteristics and antitumor immune response in patients with advancedcolon cancer. Methods: Patients with advanced colon cancer who received chemotherapyin our hospital between May 2013 and June 2016 were selected and randomly divided intothe combined chemotherapy group who received Aidi injection combined with FOLFOX4chemotherapy and the FOLFOX4 group who received FOLFOX4 chemotherapy alone. Afterchemotherapy, the serum was collected to determine the levels of tumor markers, tumorlesions were collected to determine the expression of tumor stem cell markers and immune cellmarkers, and peripheral blood mononuclear cells were collected to determine the expressionof immune cell markers. Results: After 2 and 4 cycles of treatment, serum CEA, CA199,CCSA-3 and CCSA-4 levels of combined chemotherapy group were significantly lower thanthose of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16and CD56 in peripheral blood mononuclear cells were significantly higher than those ofFOLFOX4 group; after four cycles of chemotherapy, CD133, Musashi-1, Piwil2, Nanog andSox-2 protein content in tumor lesions were significantly lower than those of FOLFOX4 group,and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 were significantlyhigher than those of FOLFOX4 group. Conclusion: Aidi injection combined with FOLFOX4chemotherapy treatment of advanced colon cancer will help reduce the tumor load, inhibittumor stem cell characteristics and enhance antitumor immune response.
机译:目的:研究艾迪注射液联合FOLFOX4化疗对晚期结肠癌患者肿瘤干细胞特性和抗肿瘤免疫反应的影响。方法:选择2013年5月至2016年6月在我院接受化疗的晚期结肠癌患者,随机分为艾迪注射液联合FOLFOX4化疗的联合化疗组和单独接受FOLFOX4化疗的FOLFOX4组。化疗后,收集血清以确定肿瘤标志物的水平,收集肿瘤以确定肿瘤干细胞标志物和免疫细胞标志物的表达,并收集外周血单核细胞以确定免疫细胞标志物的表达。结果:治疗2、4个周期后,联合化疗组的血清CEA,CA199,CCSA-3和CCSA-4水平明显低于FOLFOX4组,而CD3,CD4,CD8,CD16和CD56的平均荧光强度低于FOLFOX4组。外周血单个核细胞明显高于FOLFOX4组。经过四个周期的化疗,肿瘤病变中的CD133,Musashi-1,Piwil2,Nanog和Sox-2蛋白含量明显低于FOLFOX4组,CD3,CD4,CD8,CD16和CD56的平均荧光强度明显高于FOLFOX4组。 FOLFOX4组的那些。结论:艾迪注射液联合FOLFOX4化学疗法治疗晚期结肠癌有助于减轻肿瘤负荷,抑制肿瘤干细胞特性,增强抗肿瘤免疫反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号